Abstract IA11: Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming Free

Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. mTOR plays a central role in this process. Understanding how mTOR coordinates metabolic reprogramming may yield new insights into tumor pathogenesis, and provide a landscape of promising drug targets, while yielding important clues into mechanisms of resistance to the signal transduction inhibitors currently in use. This talk will focus on the emerging central regulatory role for mTOR complex 2 (mTORC2) in cancer metabolic reprogramming and targeted therapy resistance highlighting a recently identified, novel, Akt-independent, c-Myc-dependent pathway.

Citation Format: Paul Mischel. Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming. [abstract]. In: Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(7 Suppl):Abstract nr IA11.